NCT02322853 - A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

April 30, 2017

Conditions

PostmenopausalMetastatic Breast Cancer

Interventions

DRUG

Tamoxifen

hormonotherapy

DRUG

Ralimetinib (LY2228820 dimesylate)

Trial Locations (14)

Institut Bergonié, Bordeaux

Centre François Baclesse, Caen

Centre Jean Perrin, Clermont-Ferrand

Centre Georges-François Leclerc, Dijon

Centre Léon Bérard, Lyon

Institut Paoli Calmettes, Marseille

Institut de Cancérologie de l'Ouest, Nantes

Hegp, Ap-Hp, Paris

Hôpital St Louis, AP-HP, Paris

Centre Eugène Marquis, Rennes

Centre Henri Becquerel, Rouen

Institut Curie, Saint-Cloud

Institut Claudius Regaud, Toulouse

Institut Gustave Roussy, Villejuif